PEG-IFN alfa-2a

Phase 3Small molecule

Roche

PEG-IFN alfa-2a is one of 81 small molecule programs targeting Chronic Hepatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

Hepatitis BActive, not recruiting

Hepatitis CActive, not recruiting

Chronic HepatitisPhase 2

Active, not recruiting

Hepatitis BPhase 2

Active, not recruiting

Hepatitis CPhase 3

Active, not recruiting

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

PEG-Intron

Merck & Co.

Preclinical

43 2

Sovaldi

Gilead

Preclinical

34 3

PEG-IFN alfa-2a

Roche

Phase 3

4 4

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

199 5

Incivek

Vertex Pharmaceuticals

Preclinical

10 6

Medrol

Pfizer

Preclinical

1 7

Dasabuvir

AbbVie

Preclinical

7 8

SOF/VEL

Gilead

Preclinical

4 9

Interferon Alfa

Pfizer

Preclinical

2 10

Peg-IFN Alfa-2b

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Hepatitis4 trials

A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection

Completed· Roche logo

Roche·Phase 4·NCT00192647·896 enrolled

An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants

Completed·TTibotec BVBA·Phase 2·NCT00528528·166 enrolled

A Study to Collect Blood Biomarker Samples From Participants With Chronic Hepatitis B (CHB) Who Received Treatment With Pegasys (Peginterferon Alfa-2a) ± Nucleoside/Nucleotide Analogue

Completed· Roche logo

Roche··NCT01855997·1,669 enrolled

Show 1 more trial

An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C

Completed· Roche logo

Roche··NCT01447446·4,442 enrolled

Hepatitis C2 trials

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

Completed·TTibotec BVBA·Phase 3·NCT00703118·663 enrolled

Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C

Completed· Tanabe Pharma Corporation logo

Tanabe Pharma Corporation·Phase 3·NCT01753557·54 enrolled

Alcohol1 trial

A Bioequivalence Study of Pegylated Interferon Alfa-2a (PEG-IFN Alfa-2a) Benzyl Alcohol (BA)-Free Formulation Versus PEG-IFN Alfa-2a (Pegasys) Following Subcutaneous Administration

Completed· Roche logo

Roche·Phase 1·NCT02573025·277 enrolled

Hepatitis B1 trial

Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent

Completed·HHepatera Ltd.·Phase 2·NCT02888106·90 enrolled

Efficacy and Safety1 trial

Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

Completed·EEiger BioPharmaceuticals·Phase 3·NCT03719313·407 enrolled

2 more indications

Infection1 trial

Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection

Completed·HHepatera Ltd.·Phase 1/2·NCT02637999·24 enrolled

Advanced1 trial

Cemiplimab/Peg-Interferon-α in Advanced CSCC

Withdrawn·BBaptist Health South Florida·Phase 1·NCT05729139

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for PEG-IFN alfa-2a. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PEG-IFN alfa-2a compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PEG-IFN alfa-2a. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

PEG-IFN alfa-2a

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Hepatitis4 trials

Hepatitis C2 trials

Alcohol1 trial

Hepatitis B1 trial

Efficacy and Safety1 trial

Infection1 trial

Advanced1 trial

References

Drug Info

Quick Facts

Related News